Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis from 21 US centers Journal Article
| Authors: | Zelikson, V.; Gurumurthi, A.; Sawalha, Y.; Annunzio, K.; Saha, A.; Dong, N.; Qualls, D.; Amoozgar, B.; Kahl, B.; Baird, J.; Challa, P.; Huntington, S. F.; Santos, J.; Bair, S.; Narkhede, M.; Li, S.; Frosch, Z.; Ho, C.; Smith, S. D.; Winter, A.; Landsburg, D.; Furqan, F.; Hamadani, M.; Baird, K.; Romancik, J.; Alharthy, H.; Law, J.; Bojanini, L.; Advani, R.; Hu, B.; Johnson, P. C.; Grover, N. S.; Merril, M.; Crombie, J. L.; Shafagati, N.; Sterling, C.; Nastoupil, L. J.; Epperla, N.; Ayers, E. C. |
| Article Title: | Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: A real-world analysis from 21 US centers |
| Abstract: | Outcomes in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor. Loncastuximab-teserine (Lonca) is an antibody-drug conjugate which was approved by the Food and Drug Administration for the treatment of patients with R/R DLBCL who have received at least two prior lines of therapy, based on the results of the LOTIS-2 trial. However, there are limited data regarding its efficacy in the real-world setting. This retrospective study included 21 US centers and evaluated outcomes of patients with R/R DLBCL treated with Lonca. Our analysis comprises 187 patients with notably higher-risk baseline features compared to those of the LOTIS-2 population, including a higher proportion of patients with bulky disease (17% vs. 0%), high-grade B-cell histology (22% vs. 8%), and increased number of prior lines of therapy (median 4 vs. 3). The complete response rate was 14% and overall response rate was 32%. The median event-free survival and overall survival were 2.1 and 4.6 months, respectively. Those with bulky disease and high-grade B-cell histology had significantly worse outcomes, and those with non-germinal center cell of origin and a complete response to the most recent line of therapy demonstrated superior outcomes. In summary, in this largest retrospective cohort study of Lonca in the real-world setting, the response rates, event-free survival and overall survival were lower than those reported in LOTIS-2, which is likely reflective of its use in higher risk and more heavily pre-treated patients in the real world compared to the patients enrolled on a clinical study. ©2025 Ferrata Storti Foundation. |
| Keywords: | adult; cancer survival; event free survival; treatment outcome; treatment response; aged; aged, 80 and over; middle aged; retrospective studies; young adult; major clinical study; overall survival; lenalidomide; clinical trial; mortality; united states; cancer patient; rituximab; cancer staging; cohort analysis; relapse; recurrence; food and drug administration; drug resistance; pathology; drug resistance, neoplasm; retrospective study; histology; high risk patient; monoclonal antibody; statistical analysis; multicenter study; benzodiazepine derivative; recurrent disease; lactate dehydrogenase; lymphoma, large b-cell, diffuse; epidemiology; drug therapy; disease exacerbation; race; antibody conjugate; immunoconjugates; clinical outcome; overall response rate; diffuse large b cell lymphoma; benzodiazepines; antibodies, monoclonal, humanized; very elderly; humans; human; male; female; article; ecog performance status; antibody drug conjugate; loncastuximab tesirine |
| Journal Title: | Haematologica |
| Volume: | 110 |
| Issue: | 3 |
| ISSN: | 0390-6078 |
| Publisher: | Ferrata Storti Foundation |
| Date Published: | 2025-03-01 |
| Start Page: | 706 |
| End Page: | 714 |
| Language: | English |
| DOI: | 10.3324/haematol.2024.285977 |
| PUBMED: | 39540227 |
| PROVIDER: | scopus |
| PMCID: | PMC11873705 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work